Unspecified Gonarthrosis Osteoarthritis
Conditions
Interventions
This is a randomized, double-blind, controlled clinical trial with two arms. A total of 50 individuals who meet the eligibility criteria will be probabilistically allocated to one or the other interve
Sponsors
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Eligibility
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Age between 40 and 80 years; both genders; osteoarthritis in one or both knees grading 2 or 3 according to the Kellgren and Lawrence score and fulfilling the American College of Rheumatology criteria for knee osteoarthritis; report pain above 3 points on the Visual Analogue Scale in one or both knees
Exclusion criteria
Exclusion criteria: Use of analgesics, nonsteroidal anti-inflammatory drugs and muscle relaxants less than one week before the start of the study; Use of slow-acting drugs for osteoarthritis started less than 8 weeks before the procedure; Corticosteroid infiltration or hyaluronic acid infiltration in the six months preceding the procedure; Body Mass Index greater than kilograms per square meter; Presence of other types of arthropathies such as rheumatoid arthritis, diffuse connective tissue diseases, microcrystalline arthropathies, spondyloarthropathies and infectious arthropathies; Symptomatic osteoarthritis of the hips and feet; blood dyscrasia or use of anticoagulants, presence of other diseases such as severe depression, decompensated diabetes, coagulopathies, decompensated cardiovascular disease, infection, immunosuppression, symptomatic vascular disease of the lower limbs, neurological diseases, neoplasia or any other conditions that, in the doctor's assessment, may compromise the procedure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in Visual Analogue Scale (VAS) 0-10 cm score at 3, 6, 12 and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement on the WOMAC scale at 3, 6, 12 and 24 weeks;Improvement on the Lequesne scale at 3, 6, 12 and 24 weeks;Improvement on the KOOS scale at 3, 6, 12 and 24 weeks | — |
Countries
BR
Contacts
Public ContactDaniel Leal
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Outcome results
None listed